Zentalis Net Interest Income from 2010 to 2026
| ZNTL Stock | USD 2.46 0.12 5.13% |
Net Interest Income | First Reported 2010-12-31 | Previous Quarter 572.7 K | Current Value 469.1 K | Quarterly Volatility 79 K |
Check Zentalis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zentalis Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 167.3 K, Net Interest Income of 469.1 K or Interest Income of 469.1 K, as well as many indicators such as Price To Sales Ratio of 3.49, Dividend Yield of 0.0 or PTB Ratio of 0.7. Zentalis financial statements analysis is a perfect complement when working with Zentalis Pharmaceuticals Valuation or Volatility modules.
Zentalis | Net Interest Income | Build AI portfolio with Zentalis Stock |
Historical Net Interest Income data for Zentalis Pharmaceuticals serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Zentalis Pharmaceuticals Llc represents a compelling investment opportunity.
Latest Zentalis Pharmaceuticals' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Zentalis Pharmaceuticals Llc over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Zentalis Pharmaceuticals' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zentalis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Zentalis Net Interest Income Regression Statistics
| Arithmetic Mean | 424,991 | |
| Geometric Mean | 418,265 | |
| Coefficient Of Variation | 18.59 | |
| Mean Deviation | 74,108 | |
| Median | 355,000 | |
| Standard Deviation | 78,993 | |
| Sample Variance | 6.2B | |
| Range | 217.7K | |
| R-Value | 0.85 | |
| Mean Square Error | 1.8B | |
| R-Squared | 0.73 | |
| Significance | 0.000014 | |
| Slope | 13,334 | |
| Total Sum of Squares | 99.8B |
Zentalis Net Interest Income History
About Zentalis Pharmaceuticals Financial Statements
Zentalis Pharmaceuticals investors utilize fundamental indicators, such as Net Interest Income, to predict how Zentalis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 572.7 K | 469.1 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Zentalis Pharmaceuticals Correlation against competitors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. Anticipated expansion of Zentalis directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Zentalis Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Zentalis Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.